Literature DB >> 28986810

Recent advances in Chinese medicine for contrast-induced nephropathy.

Xue-Zhong Gong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28986810     DOI： 10.1007/s11655-017-2906-x

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


× No keyword cloud information.
  11 in total

1.  Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.

Authors:  E Chong; L Shen; K K Poh; H C Tan
Journal:  Singapore Med J       Date:  2012-03       Impact factor: 1.858

Review 2.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

3.  Protective Effects of Salvianolate on Contrast-Induced Nephropathy after Primary Percutaneous Coronary Intervention: A Prospective Multicenter Randomized Controlled Trial.

Authors:  Jing Huang; Minjie Yuan; Jian Ma; Rong Liu; Zhifeng Dong; Gang Zhao; Jingyu Hang; Junbo Wei; Shixin Ma; Meng Wei; Jinfa Jiang; Haoming Song; Zongjun Liu; Wenquan Zhang; Jingbo Li; Zhigang Lu
Journal:  Cardiology       Date:  2017-07-27       Impact factor: 1.869

4.  Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention.

Authors:  Ying Yuan; Hong Qiu; Xiaoying Hu; Tong Luo; Xiaojin Gao; Xueyan Zhao; Jun Zhang; Yuan Wu; Shubin Qiao; Yuejin Yang; Runlin Gao
Journal:  Clin Cardiol       Date:  2017-05-19       Impact factor: 2.882

5.  [Analysis of drug-induced acute renal failure in Shanghai].

Authors:  Miao-lin Che; Yu-cheng Yan; Yun Zhang; Yong Gu; Nian-song Wang; Nan Chen; Pei-ju Mao; Jin-yuan Zhang; Xiao-qiang Ding; Wei-jie Yuan; Chang-lin Mei; Jian Yao; Yu-liang Fan; Yi Zhou; Wei Zhang; Han-wei Zhu; Mei Liu; Hui-min Jin; Jia-qi Qian
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2009-03-24

6.  N-acetylcysteine amide protects renal proximal tubular epithelial cells against iohexol-induced apoptosis by blocking p38 MAPK and iNOS signaling.

Authors:  Xuezhong Gong; Gianni Celsi; Katarina Carlsson; Svante Norgren; Ming Chen
Journal:  Am J Nephrol       Date:  2009-12-17       Impact factor: 3.754

7.  Tetramethylpyrazine prevents contrast-induced nephropathy by inhibiting p38 MAPK and FoxO1 signaling pathways.

Authors:  Xuezhong Gong; Qian Wang; Xiaochun Tang; Yuerong Wang; Dan Fu; Huayi Lu; Guohua Wang; Svante Norgren
Journal:  Am J Nephrol       Date:  2013-02-26       Impact factor: 3.754

8.  Guideline adherence for identification and hydration of high-risk hospital patients for contrast-induced nephropathy.

Authors:  Janneke Schilp; Carolien de Blok; Maaike Langelaan; Peter Spreeuwenberg; Cordula Wagner
Journal:  BMC Nephrol       Date:  2014-01-06       Impact factor: 2.388

9.  Nephroprotective Effects of N-Acetylcysteine Amide against Contrast-Induced Nephropathy through Upregulating Thioredoxin-1, Inhibiting ASK1/p38MAPK Pathway, and Suppressing Oxidative Stress and Apoptosis in Rats.

Authors:  Xuezhong Gong; Yiru Duan; Junli Zheng; Yiquan Wang; Guohua Wang; Svante Norgren; Tom K Hei
Journal:  Oxid Med Cell Longev       Date:  2016-12-26       Impact factor: 6.543

10.  Contrast-induced nephropathy: pharmacology, pathophysiology and prevention.

Authors:  Remy W F Geenen; Hylke Jan Kingma; Aart J van der Molen
Journal:  Insights Imaging       Date:  2013-10-03
View more
  3 in total

Review 1.  Tetramethylpyrazine: An Active Ingredient of Chinese Herbal Medicine With Therapeutic Potential in Acute Kidney Injury and Renal Fibrosis.

Authors:  Jun Li; Xuezhong Gong
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

2.  Efficacy and Safety of Chuan Huang Fang Combining Reduced Glutathione in Treating Acute Kidney Injury (Grades 1-2) on Chronic Kidney Disease (Stages 2-4): Study Protocol for a Multicenter Randomized Controlled Clinical Trial.

Authors:  Ling Chen; Xuezhong Gong
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-15       Impact factor: 2.629

3.  Chuan Huang Fang combining reduced glutathione in treating acute kidney injury (grades 1-2) on chronic kidney disease (stages 2-4): A multicenter randomized controlled clinical trial.

Authors:  Ling Chen; Zi Ye; Danjun Wang; Jianlian Liu; Qian Wang; Chen Wang; Bing Xu; Xuezhong Gong
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.